Emergent BioSolutions (EBS) Net Cash Flow Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -62.71% |
| 10 | Emergent BioSolutions | 383.54 Mn | 222.04 Mn | 84.10 Mn | 38.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.99% |
| Dec 31, 2025 | -28.06% |
| Sep 30, 2025 | 42.95% |
| Jun 30, 2025 | 51.76% |
| Mar 31, 2025 | 32.80% |
| Dec 31, 2024 | -31.90% |
| Sep 30, 2024 | 58.25% |
| Jun 30, 2024 | 56.98% |
| Mar 31, 2024 | 23.56% |
| Dec 31, 2023 | -50.29% |
| Sep 30, 2023 | -26.26% |
| Jun 30, 2023 | -80.97% |
| Mar 31, 2023 | -159.19% |
| Dec 31, 2022 | 142.46% |
| Sep 30, 2022 | -45.06% |
| Jun 30, 2022 | -58.08% |
| Mar 31, 2022 | -96.61% |
| Dec 31, 2021 | 40.18% |
| Sep 30, 2021 | -31.82% |
| Jun 30, 2021 | -79.15% |